Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
September 01 2022 - 6:30AM
Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced that management will participate in three upcoming
investor conferences:
- Conduct one-on-one investor meetings at Citi's 17th Annual
BioPharma Conference on Thursday, September 8, 2022;
- A corporate presentation at the H.C. Wainwright 24th Annual
Global Investment Conference, at 11:30 a.m. ET on Monday, September
12, 2022; and
- A corporate presentation and fireside chat at Baird’s 2022
Global Healthcare Conference, at 4:20 p.m. ET on Tuesday, September
13, 2022.
Presentations will be available in the Investors section of the
Harpoon Therapeutics website at www.harpoontx.com with an archived
replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy
company developing a novel class of T cell engagers that harness
the power of the body’s immune system to treat patients suffering
from cancer and other diseases. T cell engagers are engineered
proteins that direct a patient’s own T cells to kill target cells
that express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Cautionary Note on Forward-looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “anticipate,” “could,” “expect,” “look
forward,” “plan,” “potential,” “target,” “goal”, “will,” “intend”,
and similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. These
forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include, but are not limited to, statements
about the development and advancement of Harpoon Therapeutics’
platforms and product candidates, including cash sufficiency
forecast, progress, plans for partnerships, timing, scope, design
and interim results of clinical trials, the safety and tolerability
profile of product candidates, and other statements that are not
historical fact. Many factors may cause differences between current
expectations and actual results, including unexpected safety or
efficacy data observed during clinical studies, preliminary data
and trends may not be predictive of future data or results, may not
demonstrate safety or efficacy or lead to regulatory approval by
the FDA or other regulatory agencies, clinical trial site
activation or enrollment rates that are lower than expected,
unanticipated or greater than anticipated impacts or delays due to
COVID-19, changes in expected or existing competition, changes in
the regulatory environment, the uncertainties and timing of the
regulatory approval process, the timing and results of unexpected
litigation or other disputes, and the sufficiency of Harpoon
Therapeutics’ cash resources. These and other factors that may
cause Harpoon Therapeutics’ actual results to differ from those
expressed or implied in the forward-looking statements in this
press release are discussed in Harpoon Therapeutics’ filings with
the U.S. Securities and Exchange Commission, including under “Risk
Factors” in Harpoon Therapeutics’ quarterly report on Form 10-Q for
the quarter ended June 30, 2022 and future filings by Harpoon
Therapeutics. Except as required by law, Harpoon Therapeutics
assumes no obligation to update any forward-looking statements
contained herein to reflect any change in expectations, even as new
information becomes available.
Contacts:
Investors:Robert UhlICR
Westwicke858-356-5932robert.uhl@westwicke.com
Media:uncapped communications862-368-4464media@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024